Vildrozon (50mg) 10 Tablets

Overview

Vildrozon 50mg 10 Tablets is an oral antidiabetic medicine containing vildagliptin 50mg as the active ingredient. Vildagliptin belongs to the dipeptidyl peptidase-4 (DPP-4) inhibitor class and is used as part of medical management for adults with type 2 diabetes mellitus when lifestyle measures alone, or existing diabetes medicines, do not provide adequate glycaemic control. This listing refers to the 50mg tablet strength and a pack size of 10 tablets; users should always verify the dispensed strip, strength and expiry date before use.

Vildrozon is not insulin and is not intended for type 1 diabetes or diabetic ketoacidosis. Blood glucose control usually also requires a diabetes meal plan, physical activity, weight management where appropriate and regular monitoring of HbA1c, fasting glucose and post-meal glucose as advised by a clinician.

Benefits

• Helps improve fasting and post-meal blood glucose control as part of a diabetes plan
• Supports glucose-dependent insulin secretion through incretin hormone activity
• Helps reduce inappropriate glucagon activity during hyperglycaemia
• Generally has lower hypoglycaemia risk when used alone than insulin-releasing medicines, although risk increases with insulin or sulfonylureas

Key Features

• Vildagliptin 50mg oral tablet
• DPP-4 inhibitor class antidiabetic medicine
• Used for adult type 2 diabetes mellitus
• Pack size: 10 tablets
• May be prescribed alone or with other diabetes medicines when clinically appropriate

Dosage and How to Use

• How to use: Swallow the tablet with water exactly as prescribed. Do not change the dose, stop treatment, or combine with other diabetes medicines unless advised by a healthcare professional.
• Administration: Oral administration.
• Recommended dose: Dose must be individualized by the prescriber. Vildagliptin is commonly prescribed as 50mg once daily or 50mg twice daily depending on the treatment combination and patient factors.
• Adult dose: Usually individualized; common adult regimens are 50mg once daily or 50mg twice daily depending on the clinical situation. Follow the prescription exactly.
• Pediatric use: Not recommended for children and adolescents under 18 years because safety and efficacy have not been established.
• Elderly use: No routine dose adjustment is generally required solely due to age, but kidney function and overall frailty should be considered by the prescriber.
• When to take: Take at the same time each day. If prescribed once daily it is commonly taken in the morning; if prescribed twice daily it is commonly taken in the morning and evening.
• With food: Vildagliptin can generally be taken with or without food unless the prescriber gives different instructions.
• Maximum daily dose: Doses above 100mg of vildagliptin per day are not recommended. Some patients, including those with renal impairment or those using sulfonylureas, may require a lower schedule as prescribed.
• Missed dose: Take the missed dose as soon as remembered unless it is nearly time for the next dose. Do not take a double dose on the same day.
• Overdose: Seek urgent medical advice, contact a poison center, or go to the nearest emergency department if overdose is suspected. Supportive medical management may be needed.

Specifications

Side Effects

Common side effects

• Headache
• Dizziness
• Tremor
• Nausea
• Vomiting
• Diarrhoea
• Constipation
• Abdominal discomfort
• Reflux
• Rash or itching
• Joint or muscle pain
• Upper respiratory symptoms

Serious side effects (seek medical help)

• Pancreatitis symptoms such as severe persistent abdominal pain with or without vomiting
• Liver problems such as jaundice, dark urine or unexplained fatigue
• Angioedema or severe allergic reaction
• Severe blistering or peeling skin reactions
• Clinically significant hypoglycaemia, especially with insulin or sulfonylureas

Allergic reaction

Stop use and seek urgent medical help for swelling of the face, lips, tongue or throat, breathing difficulty, severe rash, blistering, peeling skin or other signs of serious allergy.

Safety and Precautions

• Not for type 1 diabetes or diabetic ketoacidosis
• Not a substitute for insulin in insulin-requiring patients
• Monitor for symptoms of pancreatitis, liver dysfunction, allergic reactions, severe skin reactions, and hypoglycaemia
• Check the dispensed strength and pack carefully before use
• Tell the doctor about liver disease, kidney disease, heart failure, pancreatitis history, lactose intolerance and diabetic skin problems
• Regular blood glucose and HbA1c monitoring may be required
• Liver function testing may be required before and during therapy
• Use caution with insulin or sulfonylureas because hypoglycaemia risk can increase

When not to use

Do not use for type 1 diabetes | Do not use for diabetic ketoacidosis | Do not use in hepatic impairment or persistently elevated liver enzymes unless a specialist explicitly advises otherwise | Do not restart if pancreatitis is confirmed during treatment

Special populations

• Pregnancy: Vildagliptin should not be used during pregnancy unless a qualified clinician decides on an appropriate diabetes treatment plan. Consult a doctor before use if pregnant or planning pregnancy.
• Breastfeeding: Vildagliptin should not be used during breastfeeding unless specifically advised by a healthcare professional, as transfer into human milk is uncertain.
• Fertility: Human fertility data for vildagliptin are limited; discuss concerns with a healthcare professional.
• Liver: Vildagliptin should not be used in hepatic impairment or if baseline ALT or AST is more than three times the upper limit of normal. Liver function monitoring may be required.
• Kidney: Patients with moderate or severe renal impairment or end-stage renal disease may require a reduced dosing schedule. Kidney function should be assessed by the prescriber.
• Heart: Use caution in patients with heart failure. Use is not recommended in severe NYHA class IV heart failure due to limited clinical experience.
• Driving: Dizziness may occur. Avoid driving or operating machinery until you know how the medicine affects you, especially if hypoglycaemia is possible.
• Alcohol: Alcohol may affect blood glucose control and can increase hypoglycaemia risk in some diabetes patients. Ask the prescriber for individualized advice.

Interactions

Drugs:

• Insulin and sulfonylureas may increase hypoglycaemia risk when combined with vildagliptin
• ACE inhibitors may be associated with increased angioedema risk
• Thiazide diuretics, corticosteroids, thyroid products and sympathomimetics may reduce glucose-lowering effect
• Tell the doctor about all prescription, non-prescription and herbal products

Food:

• Food does not usually have a clinically significant effect on vildagliptin exposure, but patients should follow their diabetes meal plan and prescriber's advice.

Conditions:

• Type 1 diabetes
• Diabetic ketoacidosis
• Hepatic impairment
• Renal impairment
• History of pancreatitis
• Heart failure
• Diabetic skin complications
• Lactose-related hereditary intolerance if applicable

Storage and Disposal

• Keep in the original blister or container, protected from moisture, and follow the storage instructions printed on the pack.
• Keep out of the sight and reach of children.
• Do not dispose of unused tablets in household waste or wastewater. Ask a pharmacist about safe disposal of unwanted or expired medicine.

Disclaimer

This information is for educational and e-commerce content purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Use only as directed by a qualified healthcare professional and always read the product label and patient leaflet.